Bio-Rad Laboratories 과거 수익 실적

과거 기준 확인 0/6

Bio-Rad Laboratories의 수입은 연평균 -43%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 13.9%의 비율로 증가했습니다. 매출은 연평균 2.5%의 비율로 증가해 왔습니다.

주요 정보

-43.0%

수익 성장률

-43.2%

EPS 성장률

Life Sciences 산업 성장	26.8%
매출 성장률	2.5%
자기자본 수익률	-10.4%
순이익	-30.2%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Bio-Rad Laboratories 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:BUWA 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	2,580	-779	800	274
30 Jun 24	2,563	-1,326	797	225
31 Mar 24	2,605	-322	809	230
31 Dec 23	2,671	-637	824	241
30 Sep 23	2,720	-159	843	250
30 Jun 23	2,769	-428	853	273
31 Mar 23	2,779	-191	854	272
31 Dec 22	2,802	-3,628	825	257
30 Sep 22	2,805	-6,021	808	236
30 Jun 22	2,871	-1,930	814	234
31 Mar 22	2,896	-91	821	233
31 Dec 21	2,923	4,254	851	247
30 Sep 21	2,980	6,659	875	268
30 Jun 21	2,880	4,045	857	263
31 Mar 21	2,701	4,098	832	251
31 Dec 20	2,546	3,814	799	218
30 Sep 20	2,380	3,521	784	212
30 Jun 20	2,294	1,947	786	200
31 Mar 20	2,329	1,579	798	198
31 Dec 19	2,312	1,759	825	203
30 Sep 19	2,304	377	817	198
30 Jun 19	2,289	905	822	200
31 Mar 19	2,292	574	831	197
31 Dec 18	2,289	366	835	199
30 Sep 18	2,294	1,277	835	199
30 Jun 18	2,283	1,030	827	212
31 Mar 18	2,212	767	827	227
31 Dec 17	2,160	122	803	235
30 Sep 17	2,110	17	819	232
30 Jun 17	2,085	13	814	220
31 Mar 17	2,097	26	798	207
31 Dec 16	2,068	26	786	206
30 Sep 16	2,067	98	776	204
30 Jun 16	2,028	97	772	198
31 Mar 16	2,018	108	768	194
31 Dec 15	2,019	109	762	193
30 Sep 15	2,047	103	769	193
30 Jun 15	2,108	97	787	203
31 Mar 15	2,139	100	796	212
31 Dec 14	2,175	89	810	220
30 Sep 14	2,179	80	828	217
30 Jun 14	2,154	61	825	217
31 Mar 14	2,142	64	820	213
31 Dec 13	2,133	78	804	211

양질의 수익: BUWA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: BUWA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: BUWA 은(는) 수익성이 없으며 지난 5년 동안 연간 43% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 BUWA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: BUWA 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( 5.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: BUWA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -10.4% )을 갖습니다.

Bio-Rad Laboratories 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: US$76.26 loss per share (vs US$39.59 loss in 2Q 2023)

Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: EPS: US$13.46 (vs US$2.33 in 1Q 2023)

Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024

Recent updates

Third quarter 2024 earnings released: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)

Bio-Rad Laboratories, Inc. Announces Executive Changes

Second quarter 2024 earnings released: US$76.26 loss per share (vs US$39.59 loss in 2Q 2023)

Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024

First quarter 2024 earnings released: EPS: US$13.46 (vs US$2.33 in 1Q 2023)

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group

Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024

Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024

Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024

Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer

Full year 2023 earnings released: US$21.82 loss per share (vs US$122 loss in FY 2022)

Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024

Third quarter 2023 earnings released: EPS: US$3.65 (vs US$5.52 loss in 3Q 2022)

Bio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Chief Financial Officer, Effective November 6, 2023

Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023

Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$39.59 loss per share (vs US$31.12 loss in 2Q 2022)

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Senior VP & Chief Accounting Officer recently sold €68k worth of stock

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$2.33 (vs US$113 loss in 1Q 2022)

Executive VP recently sold €344k worth of stock

Full year 2022 earnings released: US$122 loss per share (vs US$142 profit in FY 2021)

Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Senior VP & Chief Accounting Officer recently sold €157k worth of stock

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: US$5.52 loss per share (vs US$132 profit in 3Q 2021)

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Bio-Rad Laboratories, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Senior VP & Chief Accounting Officer recently sold €274k worth of stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Second quarter 2022 earnings released: US$31.12 loss per share (vs US$30.71 profit in 2Q 2021)

Bio-Rad Laboratories, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Now 23% undervalued after recent price drop

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from Russell 1000 Value-Defensive Index

High number of new directors

First quarter 2022 earnings released: US$113 loss per share (vs US$32.77 profit in 1Q 2021)

Insufficient new directors

Bio-Rad Laboratories, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 26, 2022

Bio-Rad Laboratories, Inc. Announces Board Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$132 (vs US$44.24 in 3Q 2020)

Executive VP & CFO recently sold €186k worth of stock

Insider recently sold €404k worth of stock

Executive VP & CFO recently sold €572k worth of stock

Second quarter 2021 earnings released: EPS US$30.71 (vs US$32.59 in 2Q 2020)

Bio-Rad Launches Its Prevalence Ddpcr Sars-Cov-2 Wastewater Quantification Kit for Covid-19 Wastewater Testing

First quarter 2021 earnings released: EPS US$32.75 (vs US$22.97 in 1Q 2020)

Executive VP recently sold €276k worth of stock

Full year 2020 earnings released: EPS US$128 (vs US$58.93 in FY 2019)

Revenue beats expectations

New 90-day high: €535

Bio-Rad Laboratories, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Insider recently sold €179k worth of stock

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

New 90-day high: €490